Online inquiry

IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15819MR)

This product GTTS-WQ15819MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&IL3RA gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000733.4; NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 3563
UniProt ID P07766; P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ15819MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11721MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ13159MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-04383119
GTTS-WQ31MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 2130
GTTS-WQ4898MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ6795MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ7102MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ12216MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ9549MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA J6M0
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW